Urovant Sciences Ltd (NASDAQ:UROV) Director Acquires $33,750.00 in Stock
Urovant Sciences Ltd (NASDAQ:UROV) Director Kevin Costello purchased 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The shares were purchased at an average cost of $6.75 per share, with a total value of $33,750.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
UROV stock traded up $0.59 during midday trading on Friday, reaching $9.99. 37,592 shares of the stock were exchanged, compared to its average volume of 39,067. Urovant Sciences Ltd has a 52 week low of $4.05 and a 52 week high of $14.49. The company has a current ratio of 6.20, a quick ratio of 6.20 and a debt-to-equity ratio of 0.29. The company has a fifty day moving average price of $8.20 and a 200 day moving average price of $9.01.
Urovant Sciences (NASDAQ:UROV) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.02). As a group, sell-side analysts predict that Urovant Sciences Ltd will post -4.02 EPS for the current fiscal year.
Several brokerages have weighed in on UROV. JPMorgan Chase & Co. set a $24.00 price objective on Urovant Sciences and gave the company a “buy” rating in a report on Friday, June 14th. Zacks Investment Research cut Urovant Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, May 22nd. ValuEngine raised Urovant Sciences from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, HC Wainwright set a $28.00 price target on Urovant Sciences and gave the company a “buy” rating in a research note on Monday, June 24th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $21.63.
About Urovant Sciences
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Featured Article: How can investors find ex-dividend dates?
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.